MedTrace Logo

A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma

NCT07201064 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-10-01

No results posted yet for this study

Summary

This study is a "3+3" dose-escalation, open-label, multiple-dose clinical trial.

Conditions

Interventions

DRUG

SZ1003 injection

once every two weeks at a dose of SZ1003 injection per infusion.

Sponsors & Collaborators

  • Guangdong ProCapZoom Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-25
Primary Completion
2027-03-30
Completion
2027-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07201064 on ClinicalTrials.gov